Hydrophilic Stent Coating Inhibits Platelet Adhesion on Stent Surfaces: Initial Results In Vitro
Tim Lenz-Habijan, P Bhogal, Marcus Peters, Albrecht Bufe, Rosa Martinez Moreno, Catrin Bannewitz, Hermann Monstadt, Hans Henkes, Tim Lenz-Habijan, P Bhogal, Marcus Peters, Albrecht Bufe, Rosa Martinez Moreno, Catrin Bannewitz, Hermann Monstadt, Hans Henkes
Abstract
Background: Endovascular stents and flow diverter stents (FDS) have revolutionized the treatment of intradural aneurysms; however, the need for dual anti-platelet treatment (DAPT) limits their use and can cause additional issues. Therefore, there is a need to develop stent coatings that negate the need for DAPT.
Methods: Two different hydrophilic polymer coatings (HPC-I and HPC-II) were used to coat small nickel titanium plates to initially test the hydrophilic properties of these coatings when applied to nickel titanium. The plates were subsequently incubated with non-medicated whole blood from healthy volunteers for 10 min and stained with a CD61 immunofluorescent antibody that allows detection of adherent platelets. The coatings were applied to FDS wires and were again incubated with non-medicated whole blood from the same volunteers. Scanning electron microscopy was used to detect adherent platelets on the wire surface.
Results: The HPC-II coating (1.12 ± 0.4%) showed a significantly lower CD61 +ve cell count (p ≤ 0.001) compared to both uncoated NiTi plates (48.61 ± 7.3%) and those with the HPC-I coating (mean 40.19 ± 8.9%). Minimal adherent platelets were seen on the FDS nickel titanium wires coated with the HPC-II compared to uncoated FDS under electron microscopy.
Conclusion: There is a significant decrease in the number of adherent CD61 +ve platelets on nickel titanium surfaces coated with the HPC-II coating compared to uncoated surfaces. The coating can be successfully applied to the wires of flow diverters. The results of this study are promising with regard to the development of new anti-thrombogenic endovascular devices.
Keywords: Anti-platelet; Anti-thrombogenic coating; Flow diverter stent.
Conflict of interest statement
Conflict of interestTLH is employed in the R&D department of phenox. PB is a consultant and proctor for phenox and Neurvana Medical. MP, AB declared no conflict of interests. RMM is a consultant and proctor for phenox. HH is a co-founder and shareholder of phenox. HM is a co-founder, shareholder and CEO of phenox.
Ethical StatementAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Figures
References
- Kadirvel R, Ding Y-H, Dai D, Rezek I, Lewis DA, Kallmes DF. Cellular mechanisms of aneurysm occlusion after treatment with a flow diverter. Radiology. 2014;270:394–399. doi: 10.1148/radiol.13130796.
- Becske T, Kallmes DF, Saatci I, McDougall CG, Szikora I, Lanzino G, et al. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. Radiology. 2013;267:858–868. doi: 10.1148/radiol.13120099.
- Nelson PK, Lylyk P, Szikora I, Wetzel SG, Wanke I, Fiorella D. The pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol. 2011;32:34–40. doi: 10.3174/ajnr.A2421.
- Briganti F, Leone G, Marseglia M, Mariniello G, Caranci F, Brunetti A, et al. Endovascular treatment of cerebral aneurysms using flow-diverter devices: a systematic review. Neuroradiol J. 2015;28:365–375. doi: 10.1177/1971400915602803.
- Mpotsaris A, Skalej M, Beuing O, Eckert B, Behme D, Weber W. Long-term occlusion results with SILK flow diversion in 28 aneurysms: do recanalizations occur during follow-up? Interv Neuroradiol J Peritherapeutic Neuroradiol Surg Proced Relat Neurosci. 2015;21:300–310.
- Strauss I, Maimon S. Silk flow diverter in the treatment of complex intracranial aneurysms: a single-center experience with 60 patients. Acta Neurochir (Wien) 2016;158:247–254. doi: 10.1007/s00701-015-2644-9.
- Kocer N, Islak C, Kizilkilic O, Kocak B, Saglam M, Tureci E. Flow Re-direction Endoluminal Device in treatment of cerebral aneurysms: initial experience with short-term follow-up results. J Neurosurg. 2014;120:1158–1171. doi: 10.3171/2014.1.JNS131442.
- Saatci I, Yavuz K, Ozer C, Geyik S, Cekirge HS. Treatment of intracranial aneurysms using the pipeline flow-diverter embolization device: a single-center experience with long-term follow-up results. AJNR Am J Neuroradiol. 2012;33:1436–1446. doi: 10.3174/ajnr.A3246.
- Fischer S, Vajda Z, Aguilar Perez M, Schmid E, Hopf N, Bäzner H, et al. Pipeline embolization device (PED) for neurovascular reconstruction: initial experience in the treatment of 101 intracranial aneurysms and dissections. Neuroradiology. 2012;54:369–382. doi: 10.1007/s00234-011-0948-x.
- Bhogal P, Pérez MA, Ganslandt O, Bäzner H, Henkes H, Fischer S. Treatment of posterior circulation non-saccular aneurysms with flow diverters: a single-center experience and review of 56 patients. J Neurointerventional Surg. 2016;9:471–481. doi: 10.1136/neurintsurg-2016-012781.
- Bhogal P, Martinez Moreno R, Ganslandt O, Bäzner H, Henkes H, Perez MA. Use of flow diverters in the treatment of unruptured saccular aneurysms of the anterior cerebral artery. J Neurointerventional Surg. 2017;9:283–289. doi: 10.1136/neurintsurg-2016-012648.
- Bhogal P, Hellstern V, Bäzner H, Ganslandt O, Henkes H, Aguilar Pérez M. The use of flow diverting stents to treat para-ophthalmic aneurysms. Front Neurol. 2017;8:381. doi: 10.3389/fneur.2017.00381.
- Bhogal P, Ganslandt O, Bäzner H, Henkes H, Pérez MA. The fate of side branches covered by flow diverters-results from 140 patients. World Neurosurg. 2017;103:789–798. doi: 10.1016/j.wneu.2017.04.092.
- Dotter CT. Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. Invest Radiol. 1969;4:329–332. doi: 10.1097/00004424-196909000-00008.
- Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–1671. doi: 10.1056/NEJM199812033392303.
- Kastrati A, Schühlen H, Hausleiter J, Walter H, Zitzmann-Roth E, Hadamitzky M, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997;96:462–467.
- Chen C, Lumsden AB, Ofenloch JC, Noe B, Campbell EJ, Stratford PW, et al. Phosphorylcholine coating of ePTFE grafts reduces neointimal hyperplasia in canine model. Ann Vasc Surg. 1997;11:74–79. doi: 10.1007/s100169900013.
- Chen C, Ofenloch JC, Yianni YP, Hanson SR, Lumsden AB. Phosphorylcholine coating of ePTFE reduces platelet deposition and neointimal hyperplasia in arteriovenous grafts. J Surg Res. 1998;77:119–125. doi: 10.1006/jsre.1998.5399.
- Campbell EJ, O’Byrne V, Stratford PW, Quirk I, Vick TA, Wiles MC, et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J Am Soc Artif Intern Organs. 1992;1994(40):M853–M857.
- Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;91:2645–2657.
- Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25:5681–5703. doi: 10.1016/j.biomaterials.2004.01.023.
- Mikhalovska LI, Santin M, Denyer SP, Lloyd AW, Teer DG, Field S, et al. Fibrinogen adsorption and platelet adhesion to metal and carbon coatings. Thromb Haemost. 2004;92:1032–1039.
- Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93:327–358. doi: 10.1152/physrev.00016.2011.
- Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemoph Off J World Fed Hemoph. 2008;14(Suppl 5):11–26. doi: 10.1111/j.1365-2516.2008.01848.x.
- Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, et al. Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the pipeline embolization device. AJNR Am J Neuroradiol. 2014;35:128–135. doi: 10.3174/ajnr.A3621.
- Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, et al. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. J Neurointerventional Surg. 2013;5(Suppl 3):iii3–iii10. doi: 10.1136/neurintsurg-2012-010582.
- Daou B, Starke RM, Chalouhi N, Barros G, Tjoumakaris S, Rosenwasser RH, et al. P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the pipeline embolization device. Neurosurgery. 2016;78:27–33. doi: 10.1227/NEU.0000000000000978.
- Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003;108:2–5. doi: 10.1161/01.CIR.0000075929.79964.D8.
- Moulakakis KG, Mylonas SN, Lazaris A, Tsivgoulis G, Kakisis J, Sfyroeras GS, et al. Acute carotid stent thrombosis: a comprehensive review. Vasc Endovascular Surg. 2016;50:511–521. doi: 10.1177/1538574416665986.
- Riedel CH, Tietke M, Alfke K, Stingele R, Jansen O. Subacute stent thrombosis in intracranial stenting. Stroke. 2009;40:1310–1314. doi: 10.1161/STROKEAHA.108.531400.
- Lopez-Donaire ML, Santerre JP. Surface modifying oligomers used to functionalize polymeric surfaces: consideration of blood contact applications. J Appl Polym Sci. 2014;131:40328. doi: 10.1002/app.40328.
- Muramatsu T, Onuma Y, Zhang Y-J, Bourantas CV, Kharlamov A, Diletti R, et al. Progress in treatment by percutaneous coronary intervention: the stent of the future. Rev Espanola Cardiol Engl Ed. 2013;66:483–496. doi: 10.1016/j.recesp.2012.12.009.
- Kaplan O, Hierlemann T, Krajewski S, Kurz J, Nevoralová M, Houska M, et al. Low-thrombogenic fibrin-heparin coating promotes in vitro endothelialization. J Biomed Mater Res A. 2017;105:2995–3005. doi: 10.1002/jbm.a.36152.
- Shuvalova YA, Shirokov RO, Kaminnaya VI, Samko AN, Kaminnyi AI. Two-year follow-up of percutaneous coronary intervention using EucaTax or Cypher. Cardiovasc Revascularization Med Mol Interv. 2013;14:284–288. doi: 10.1016/j.carrev.2013.07.005.
- Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, et al. 9-month clinical and angiographic outcomes of the COBRA polyzene-F nanocoated coronary stent system. JACC Cardiovasc Interv. 2017;10:160–167. doi: 10.1016/j.jcin.2016.10.037.
- Marosfoi M, Clarencon F, Langan ET, King RM, Brooks OW, Tamura T, et al. Acute thrombus formation on phosphorylcholine surface modified flow diverters. J Neurointerventional Surg. 2017;10:406–411. doi: 10.1136/neurintsurg-2017-013175.
- Hagen MW, Girdhar G, Wainwright J, Hinds MT. Thrombogenicity of flow diverters in an ex vivo shunt model: effect of phosphorylcholine surface modification. J Neurointerventional Surg. 2017;9:1006–1011. doi: 10.1136/neurintsurg-2016-012612.
- Chiu AHY, Ramesh R, Wenderoth J, Davies M, Cheung A. Use of aspirin as sole oral antiplatelet therapy in acute flow diversion for ruptured dissecting aneurysms. J Neurointerventional Surg. 2017;9:e18. doi: 10.1136/neurintsurg-2016-012657.rep.
- Hanel RA, Aguilar-Salinas P, Brasiliense LB, Sauvageau E, et al. First US experience with pipeline flex with shield technology using aspirin as antiplatelet monotherapy. BMJ Case Rep. 2017 doi: 10.1136/bcr-2017-219406.
- Orlov K, Kislitsin D, Strelnikov N, Berestov V, Gorbatykh A, Shayakhmetov T, et al. Experience using pipeline embolization device with Shield Technology in a patient lacking a full postoperative dual antiplatelet therapy regimen. Interv Neuroradiol J Peritherapeutic Neuroradiol Surg Proced Relat Neurosci. 2018 doi: 10.1177/1591019917753824.
- Martínez-Galdámez M, Lamin SM, Lagios KG, Liebig T, Ciceri EF, Chapot R, et al. Periprocedural outcomes and early safety with the use of the Pipeline Flex Embolization Device with Shield Technology for unruptured intracranial aneurysms: preliminary results from a prospective clinical study. J Neurointerventional Surg. 2017;9:772–776. doi: 10.1136/neurintsurg-2016-012896.
Source: PubMed